Newer Drug-Eluting Stents May Put Late Thrombosis Issues To Rest – Meta-Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
In an analysis of about 50,000 patients in 49 different clinical studies, cobalt-chromium everolimus-eluting stents like Abbott’s Xience showed a definitive thrombosis advantage over bare-metal stents at one year and two years following the initial procedure.